Intratumor CD4 T-cell accumulation requires stronger priming than for expansion and lymphokine secretion

Cancer Research

Volumn 66, Issue 10, 2006, Pages 5443-5451

  Joncker, Nathalie T ^a   Helft, Julie ^a   Jacquet, Alexandra ^a   Premel, Virginie ^a   Lantz, Olivier ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DBY ANTIGEN; DEAD BOX PROTEIN; GAMMA INTERFERON; LYMPHOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; LAMINA PROPRIA; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL MOVEMENT; DEAD-BOX RNA HELICASES; DNA-BINDING PROTEINS; EPITOPES, T-LYMPHOCYTE; FEMALE; FIBROSARCOMA; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOKINES; MALE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PROTEINS; RECEPTORS, ANTIGEN, T-CELL;

EID: 33744945798     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3526     Document Type: Article

References (40)

1. Braun MY, Grandjean I, Feunou P, et al. Acute rejection in the absence of cognate recognition of allograft by T cells. J Immunol 2001;166:4879-83.
2. Braun MY, McCormack A, Webb G, Batchelor JR. Mediation of acute but not chronic rejection of MHC-incompatible rat kidney grafts by alloreactive CD4 T cells activated by the direct pathway of sensitization. Transplantation 1993;55:177-82.
3. Toes REM, Ossendorp F, Offringa R, Melief CJM. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753-6.
4. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc Natl Acad Sci USA 1999;96:8633-8.
5. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN γ receptor expression by nonhematopoietic cells. Immunity 2000;12:677-86.
6. + T cells. Immunity 2005;22:371-83.
7. Marzo AL, Lake RA, Lo D, et al. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 1999;162:5838-45.
8. Nelson DJ, Mukherjee S, Bundell C, Fisher S, van Hagen D, Robinson B. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J Immunol 2001;166:5557-66.
9. Nguyen LT, Elford AR, Murakami K, et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 2002;195:423-35.
10. Kim SK, Schluns KS, Lefrancois L. Induction and visualization of mucosal memory CD8 T cells following systemic virus infection. J Immunol 1999;163:4125-32.
11. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001;410:101-5.
12. Reinhardt RL, Bullard DC, Weaver CT, Jenkins MK. Preferential accumulation of antigen-specific effector CD4 T cells at an antigen injection site involves CD62E-dependent migration but not local proliferation. J Exp Med 2003;197:751-62.
13. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment- specific lymphocyte homing. Curr Opin Immunol 2000;12:336-41.
14. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 2002;195:135-41.
15. Calzascia T, Masson F, Di Berardino-Besson W, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 2005;22:175-84.
16. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001;15:445-55.
17. Song J, So T, Cheng M, Tang X, Croft M. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 2005;22:621-31.
18. Matis LA, Glimcher LH, Paul WE, Schwartz RH. Magnitude of response of histocompatibility-restricted T-cell clones is a function of the product of the concentrations of antigen and Ia molecules. Proc Natl Acad Sci U S A 1983;80:6019-23.
19. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998;8:89-95.
20. Langenkamp A, Casorati G, Garavaglia C, Dellabona P, Lanzavecchia A, Sallusto F. T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur J Immunol 2002;32:2046-54.
21. Reay PA, Matsui K, Haase K, Wulfing C, Chien YH, Davis MM. Determination of the relationship between T cell responsiveness and the number of MHC-peptide complexes using specific monoclonal antibodies. J Immunol 2000;164:5626-34.
22. Irvine DJ, Purbhoo MA, Krogsgaard M, Davis MM. Direct observation of ligand recognition by T cells. Nature 2002;419:845-9.
23. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001;291:2413-7.
24. Bird JJ, Brown DR, Mullen AC, et al. Helper T cell differentiation is controlled by the cell cycle. Immunity 1998;9:229-37.
25. Boissonnas A, Combadiere C, Lavergne E, et al. Antigen distribution drives programmed antitumor CDS cell migration and determines its efficiency. J Immunol 2004;173:222-9.
26. Joncker NT, Marloie MA, Chernysheva A, et al. Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. Int J Cancer 2006;118:1205-14.
27. + T cells through the indirect presentation pathway in vivo. J Immunol 2003;171:6510-8.
28. + T cell survival but not for antigen proliferation. Nat Immunol 2000;1:54-8.
29. + T cells by dendritic cell-derived exosomes. Nat Immunol 2002;3:1156-62.
30. Schwartz D. Méthodes statistiques à l'usage des médecins et des biologistes. Paris: Flammarion; 1963.
31. Cuenca A, Cheng F, Wang H, et al. Extralymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 2003;63:9007-15.
32. Kim SK, Reed DS, Olson S, et al. Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals. Proc Natl Acad Sci USA 1998;95:10814-9.
33. Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res 2005;65:2001-8.
34. Opferman JT, Ober BT, Ashton-Rickardt PG. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science 1999;283:1745-8.
35. + T cell proliferation and effector function in vivo. Immunity 2000;13:291-301.
36. Gudmundsdottir H, Wells AD, Turka LA. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J Immunol 1999;162:5212-23.
37. Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002;12:33-42.
38. + T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol 2004;173:7209-16.
39. + T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
40. Lazarski CA, Chaves FA, Jenks SA, et al. The kinetic stability of MHC class II: peptide complexes is a key parameter that dictates immunodominance. Immunity 2005;23:29-40.